Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
5.60
-0.22 (-3.78%)
Dec 2, 2022 4:00 PM EST - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Selling, General & Admin
|
7.28 | 1.35 | 0.93 |
| Research & Development
|
12.31 | 8 | 8.58 |
| Operating Expenses
|
19.58 | 9.35 | 9.5 |
| Operating Income
|
-19.58 | -9.35 | -9.5 |
| Other Expense / Income
|
81.02 | -2.02 | -1.6 |
| Pretax Income
|
-100.61 | -7.33 | -7.91 |
| Net Income
|
-100.61 | -7.33 | -7.91 |
| Preferred Dividends
|
0 | 0 | -0.22 |
| Net Income Common
|
-100.61 | -7.33 | -7.69 |
| Shares Outstanding (Basic)
|
20 | 0 | 0 |
| Shares Outstanding (Diluted)
|
20 | 0 | 0 |
| Shares Change
|
4685.59% | -2.71% | - |
| EPS (Basic)
|
-5.02 | -17.48 | -17.84 |
| EPS (Diluted)
|
-5.02 | -17.48 | -17.84 |
| Free Cash Flow Per Share
|
-0.90 | -17.77 | -15.83 |
| EBITDA
|
-100.6 | -7.33 | -7.91 |
| Depreciation & Amortization
|
0 | 0 | 0 |
| EBIT
|
-100.61 | -7.33 | -7.91 |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).